Muehlemann M, Miller K D, Dauphinee M, Mizejewski G J
Serometrix Biotechnology, Syracuse, NY, USA.
Cancer Metastasis Rev. 2005 Sep;24(3):441-67. doi: 10.1007/s10555-005-5135-2.
This review surveys the biological activities of an alpha-fetoprotein (AFP) derived peptide termed the Growth Inhibitory Peptide (GIP), which is a synthetic 34 amino acid segment produced from the full length 590 amino acid AFP molecule. The GIP has been shown to be growth-suppressive in both fetal and tumor cells but not in adult terminally-differentiated cells. The mechanism of action of this peptide has not been fully elucidated; however, GIP is highly interactive at the plasma membrane surface in cellular events such as endocytosis, cell contact inhibition and cytoskeleton-induced cell shape changes. The GIP was shown to be growth-suppressive in nine human tumor types and to suppress the spread of tumor infiltrates and metastases in human and mouse mammary cancers. The AFP-derived peptide and its subfragments were also shown to inhibit tumor cell adhesion to extracellular matrix (ECM) proteins and to block platelet aggregation; thus it was expected that the GIP would inhibit cell spreading/migration and metastatic infiltration into host tissues such as lung and pancreas. It was further found that the cyclic versus linear configuration of GIP determined its biological and anti-cancer efficacy. Genbank amino acid sequence identities with a variety of integrin alpha/beta chain proteins supported the GIP's linkage to inhibition of tumor cell adhesion and platelet aggregation. The combined properties of tumor growth suppression, prevention of tumor cell-to-ECM adhesion, and inhibition of platelet aggregation indicate that tumor-to-platelet interactions present promising targets for GIP as an anti-metastatic agent. Finally, based on cholinergic studies, it was proposed that GIP could influence the enzymatic activity of membrane acetylcholinesterases during tumor growth and metastasis. It was concluded that the GIP derived from full-length AFP represents a growth inhibitory motif possessing instrinsic properties that allow it to interfere in cell surface events such as adhesion, migration, metastasis, and aggregation of tumor cells.
本综述探讨了一种源自甲胎蛋白(AFP)的肽——生长抑制肽(GIP)的生物学活性。GIP是从全长590个氨基酸的AFP分子中提取的一段34个氨基酸的合成片段。研究表明,GIP对胎儿细胞和肿瘤细胞均有生长抑制作用,但对成年终末分化细胞无此作用。该肽的作用机制尚未完全阐明;然而,在诸如内吞作用、细胞接触抑制和细胞骨架诱导的细胞形态变化等细胞事件中,GIP在质膜表面具有高度的相互作用。研究表明,GIP对九种人类肿瘤类型具有生长抑制作用,并能抑制人类和小鼠乳腺癌中肿瘤浸润和转移的扩散。源自AFP的肽及其亚片段还显示出抑制肿瘤细胞与细胞外基质(ECM)蛋白的粘附,并阻止血小板聚集;因此,预计GIP将抑制细胞铺展/迁移以及向肺和胰腺等宿主组织的转移浸润。进一步发现,GIP的环状与线性构型决定了其生物学和抗癌功效。与多种整合素α/β链蛋白的Genbank氨基酸序列同一性支持了GIP与抑制肿瘤细胞粘附和血小板聚集的联系。肿瘤生长抑制、预防肿瘤细胞与ECM粘附以及抑制血小板聚集的综合特性表明,肿瘤与血小板的相互作用为GIP作为抗转移剂提供了有前景的靶点。最后,基于胆碱能研究,有人提出GIP可能在肿瘤生长和转移过程中影响膜乙酰胆碱酯酶的酶活性。结论是,源自全长AFP的GIP代表了一种生长抑制基序,其固有特性使其能够干扰肿瘤细胞的粘附、迁移、转移和聚集等细胞表面事件。